These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 25907508)

  • 1. Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1237-1245. PubMed ID: 25907508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to multikinase inhibitor actions mediated by insulin like growth factor-1.
    Lippolis C; Refolo MG; D'Alessandro R; Carella N; Messa C; Cavallini A; Carr BI
    J Exp Clin Cancer Res; 2015 Sep; 34(1):90. PubMed ID: 26329608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
    D'Alessandro R; Refolo MG; Lippolis C; Giannuzzi G; Carella N; Messa C; Cavallini A; Carr BI
    BMC Cancer; 2014 May; 14():351. PubMed ID: 24885890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regorafenib induces extrinsic and intrinsic apoptosis through inhibition of ERK/NF-κB activation in hepatocellular carcinoma cells.
    Tsai JJ; Pan PJ; Hsu FT
    Oncol Rep; 2017 Feb; 37(2):1036-1044. PubMed ID: 28000898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
    J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R; Refolo MG; Lippolis C; Carella N; Messa C; Cavallini A; Carr BI
    Cell Oncol (Dordr); 2018 Jun; 41(3):283-296. PubMed ID: 29470830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
    Carr BI; D'Alessandro R; Refolo MG; Iacovazzi PA; Lippolis C; Messa C; Cavallini A; Correale M; Di Carlo A
    J Cell Physiol; 2013 Jun; 228(6):1344-50. PubMed ID: 23169148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
    Xiao Y; Yan W; Guo L; Meng C; Li B; Neves H; Chen PC; Li L; Huang Y; Kwok HF; Lin Y
    Mol Med Rep; 2017 Feb; 15(2):941-947. PubMed ID: 28035421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversibility of regorafenib effects in hepatocellular carcinoma cells.
    D'Alessandro R; Refolo MG; Lippolis C; Messa C; Cavallini A; Rossi R; Resta L; Di Carlo A; Carr BI
    Cancer Chemother Pharmacol; 2013 Oct; 72(4):869-77. PubMed ID: 23959464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
    Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with a New Barbituric Acid Derivative Exerts Antiproliferative and Antimigratory Effects against Sorafenib Resistance in Hepatocellular Carcinoma.
    Liao YJ; Hsu SM; Chien CY; Wang YH; Hsu MH; Suk FM
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32575795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
    Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
    Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chlorogenic Acid Improves the Regorafenib Effects in Human Hepatocellular Carcinoma Cells.
    Refolo MG; Lippolis C; Carella N; Cavallini A; Messa C; D'Alessandro R
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
    Dong S; Kong J; Kong F; Kong J; Gao J; Ji L; Pan B; Chen L; Zheng L; Sun W
    BMC Cancer; 2015 Nov; 15():939. PubMed ID: 26620566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families.
    He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL
    Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
    Wei JC; Meng FD; Qu K; Wang ZX; Wu QF; Zhang LQ; Pang Q; Liu C
    Acta Pharmacol Sin; 2015 Feb; 36(2):241-51. PubMed ID: 25557114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
    Sieghart W; Pinter M; Dauser B; Rohr-Udilova N; Piguet AC; Prager G; Hayden H; Dienes HP; Dufour JF; Peck-Radosavljevic M
    J Hepatol; 2012 Sep; 57(3):592-9. PubMed ID: 22634341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
    Tuchen M; Wilisch-Neumann A; Daniel EA; Baldauf L; Pachow D; Scholz J; Angenstein F; Stork O; Kirches E; Mawrin C
    Eur J Cancer; 2017 Mar; 73():9-21. PubMed ID: 28082204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.